In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying ...

For the 12% of adults in the U.S. now taking a weight-loss medication that targets the GLP-1 and/or GIP hormones to restrict ...

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

The diabetes drug, Ozempic, has been in the headlines, causing quite a stir. Senior writer for Drugwatch.com, Terry Turner, ...

Ken Griffin started the Citadel hedge fund in 1990. In the third quarter, Griffin and Citadel more than tripled its stake in ...